CC
ATYR

Cypress Capital’s aTyr Pharma ATYR Stock Holding History

Cypress Capital’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-200
Closed -$312 – 382
2024
Q2 		$312 Buy
+200
New +$348 ﹤0.01% 365

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cypress Capital's ATYR Position: Q3 2024 in Review

Cypress Capital sold out of aTyr Pharma (ATYR) in Q3 2024, closing a stake of 200 shares — an estimated $312 sold.

Cypress Capital first reported a position in ATYR in Q2 2024 and held it in 1 quarter. The position peaked at $312 in Q2 2024. 56 funds tracked by Wall St. Rank hold ATYR as of Q3 2024.

  • Cypress Capital reported no remaining aTyr Pharma position as of Q3 2024 after selling out during the quarter.
  • Cypress Capital sold 200 aTyr Pharma shares in Q3 2024, an estimated $312.
  • Cypress Capital first reported a position in aTyr Pharma in Q2 2024 and held it in 1 quarter.
  • Cypress Capital's aTyr Pharma position peaked at $312 in Q2 2024.
  • 56 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2024.

Based on Cypress Capital's 13F filing for Q3 2024, filed 12 Nov 2024.